Fabry's disease: Clinical aspects and therapeutic perspectives;Maladie de Fabry: Aspects cliniques et perspectives therapeutiques

Schweizerische Medizinische Wochenschrift

Volumn 130, Issue 21, 2000, Pages 763-771

  Barbey, F ^a,b   Lidove, O ^a   Droz, D ^a   Griinfeld, J P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Bourse la Soc Academique Vaudoise   (Switzerland)

Author keywords

galactosidase A; Fabry's disease; Gene therapy; Human recombinant enzyme; Lysosomal disease

Indexed keywords

ALPHA GALACTOSIDASE;

CLINICAL FEATURE; ENZYME RECONSTITUTION; FABRY DISEASE; GENE THERAPY; HUMAN; REVIEW;

ANIMALS; FABRY DISEASE; FEMALE; GENE THERAPY; HETEROZYGOTE DETECTION; HUMANS; MALE; MICE; MICE, KNOCKOUT;

EID: 0034720671     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphil 1898;43:187-200.
2. Anderson W. A case of "Angeio-Keratoma". Br J Dermatol 1898;10:113-7.
3. Sweeley CC, Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963;238:1348-50.
4. Desnick RJ, Ioannou YA, Eng CM. Fabry's disease: alphagalactosidase A deficiency. In: Seriver CR, Beaudet AI., Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: Mc Graw-Hill; 1995. p. 2741-84.
5. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H. Angiokeratoma corporis diffusum - Fabry's disease. Helv Med Acta 1967;34:67-83.
6. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, et al. α-galactosidase A deficient mice: a model of Fabry's disease. Proc Natl Acad Sci USA 1997;94: 2540-4.
7. Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette PC, Romanczuk H, et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther 1999;10:1667-82.
8. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ. Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 1973;23:871-5.
9. Wise D, Wallace HJ, Jellinek EH. Angiokeratoma corporis diffusum - a clinical study of eight affected families. QJM 1962;122:177-206.
10. Sheth KJ, Bernhard GC. The arthropathy of Fabry's disease. Arthritis Rheum 1979;22:781-3.
11. Wallace RD, Cooper WJ. Angiokeratoma corporis diffusum universale (Fabry). Am J Med 1965;39:656-61.
12. Hamburger J, Dormont J, de Montera H, Hinglais N. Sur une singulière malformation familiale de l'épithélium rénal. Schweiz Med Wochenschr 1964;94:871-6.
13. Cable WJL., Kolodny EH, Adams RD. Fabry's disease: impaired autonomic function. Neurology 1982;32:498-502.
14. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979;97:671-6.
15. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8-17.
16. Grewal RP. Psychiatric disorders in patients with Fabry's disease. Int J Psychiatry Med 1993;23:307-12.
17. Moumdjian R, Tampieri D, Melanson D, Ethier R. Anderson-Fabry disease: a case report with MR, CT, and cerebral angiography. Am J Neuroradiol 1989;10:S69-S70.
18. Sheth KJ, Roth DA, Adams MB. Early renal failure in Fabry's disease. Am J Kidney Dis 1983;2:651-4.
19. Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry's disease. Am J Cardiol 1969;24:95-110.
20. Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Am J Cardiol 1975;36: 829-35.
21. Cohen IR, Fluri-Lundeen J, Wharton TP. Two-dimensional echocardiographic similarity of Fabry's disease to cardiac amyloidosis: a function of ultrastructural analogy? J Clin Ultrasound 1983;11:437-41.
22. Matsui S, Murakami E, Takekoshi N, Nakatou H, Enyama H, Takeda F. Myocardial tissue characterization by magnetic imaging in Fabry's disease. Am Heart J 1989; 117:472-4.
23. Desnick RJ, Blieden I.C, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry's disease. Circulation 1976;54:818-25.
24. Perdu J, Joly D, Lidove O. Œdème pulmonaire aigu fébrile chez un hémodialysé. Méd Thérap 1998;4:675-80.
25. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, et al. Pulmonary involvement in Fabry's disease. Am J Respir Crit Care Med 1997;155:1004-10.
26. O'Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, et al. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease, Gastroenterol 1982;82:957-62.
27. Johnston AW, Weller SD, Warland BJ. Angiokeratoma corporis diffusum: some clinical aspects. Arch Dis Child 1968; 43:73-9.
28. von Scheidt W, Eng CM. Fitzmaurice TF, Erdmann E, Hübner G, Olsen EGJ, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
29. Ogawa K, Sugamata K, Funamoto N, Abe T, Sato T, Nagashima K, et al. Restricted accumulation of globotriaosyl-ceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol 1990;21:1067-73.
30. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A. Tahara M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333: 288-93.
31. Burda CD, Winder PR. Angiokeratoma corporis diffusum universale (Fabry's disease) in female subjects. Am J Med 1967;42:293-301.
32. Lyon MF, Gene action in the H-chromosome of the mouse (Mus musculus I.) Nature 1961;190:372-3.
33. Burkholder PM, Updike SJ, Ware RA, Reese OG. Clinicopathologic, enzymatic, and genetic features in a case of Fabry's disease. Arch Pathol Lab Med 1980;104:17-25.
34. Romeo G, Migeon BR. Genetic inactivation of the alphagalactosidase locus in carriers of Fabry's disease. Science 1970;170:180-1.
35. Lemansky P, Bishop DF, Desnick RJ, Hasilik A, von Figura K. Synthesis and processing of α-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry's disease. J Biol Chem 1987;262:2062-5.
36. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Kriwit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. J Lab Clin Med 1973;81:157-71.
37. Gubler MC, Antignac C, Niaudet P, Broyer M. La biopsie rénale dans les maladies héréditaires métaboliques. In: Droz D, Lantz B, éds. La biopsie rénale. Les éditions Inserm; 1996. p. 421-39.
38. Desnick RJ, Bernstein HS, Astrin KH, Bishop DF, Fabry's disease: molecular diagnosis of hemizygotes and heterozygotes. Enzyme 1987;38:54-64.
39. Desnick RJ, Eng CM. Fabry's disease and the lipidoses. In: Morgan SH, Grünfeld JP, eds. Inherited Disorders of the Kidney. Oxford: Oxford University Press; 1998. p. 355-83.
40. Germain D, Biasotto M, Tosi T, Meo T, Kahn A, Poenaru L, Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry's disease. Hum Genet 1996;98: 719-26.
41. Popli S, Molnar ZV, Leehey DJ, Daugirdas JT, Roth DA, Adams MB, et al. Involvement of renal allograft by Fabry's disease. Am J Nephrol 1987;7:316-8.
42. Grünfeld JP, Le Porrier M, Droz D. Bensaude I, Hinglais N, Crosnier J. La transplantation rénale chez les sujets atteints de la maladie de Fabry. Nouv Presse Méd 1975;29:2081-5.
43. Kleijer WJ, Hussaarts-Odijk LM, Sacks ES, Jahoda MGJ, Niermeijer MF. Prenatal diagnosis of Fabry's disease by direct analysis of chorionic villi. Prenat Diagn 1987;7:283-7.
44. Lenoir G, Rivron M. Gubler MC, Dufier JL, Tome FSM, Guivarch M. La Maladie de Fabry: traitement du syndrome acrodyniforme par la carbamazepine. Arch Franç Péd 1977; 34:704-16.
45. Cantor WJ, Daly P, Iwanochko M, Clarke JTR, Cusimano RJ, Butany J. Cardiac transplantation for Fabry's disease. Can J Cardiol 1998;14:81-4.
46. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
47. Donati D, Novario R. Gastaldi L. Natural history and treatment of uremia secondary to Fabry's disease: an European experience. Nephron 1987;46:353-9.
48. Mosnier JF, Degott C, Bedrossian J, Molas G, Degos F, Pruna A, et al. Recurrence of Fabry's disease in a renal allograft eleven years after successful renal transplantation. Transplantation 1991;51:759-62.
49. Gantenbein H, Bruder E, Burger HR, Briner J, Binswanger U. Recurrence of Fabry's disease in a renal allograft 14 years after transplantation. Nephrol Dial Transplant 1995;10: 287-9.
50. Spence MW, Mac Kinnon KE, Burgess JK, d'Entremont DM, Belitsky P, Lannon SG, et al. Failure to correct the metabolic defect by renal allotransplantation in Fabry's disease. Ann Intern Med 1976;84:13-6.
51. Maizel SE, Simmons RI., Kjellstrand C, Fryd DS. Ten-year experience in renal transplantation for Fabry's disease. Transplant Proc 1981;13:57-9.
52. Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF, et al. Light- and electron-microscopic histochemistry of Fabry's disease. Am J Path 1981;103:247-62.
53. Brady RO, Tallman JF. Johnson WG, Gal AE, Leahy WR, Quirk JM, et al. Replacement therapy for inherited enzyme deficiency. N Engl J Med 1973;289:9-14.
54. Mayes JS, Cray EL, Dell VA, Scheerer JB, Sifers RN. Endocytosis of lysosomal α-galactosidasc A by cultured fibroblasts from patients with Fabry's disease. Am J Hum Genet 1982;34:602-10.
55. Mapes CA, Anderson RL, Sweeley CC, Desnick RJ, Krivit W. Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science 1970;169:987-9.
56. Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC. Enzyme therapy in Fabry's disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci USA 1979;76:5326-30.
57. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5;112-5.
58. Poenaru L. Thérapie génique des maladies lysosomales. Méd Sciences 1996;12:35-46.
59. Elstein D, Klutstein MW, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A. Echographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 1998;351:1544-6.
60. Lidove O. Maladie de Fabry (34 cas): manifestations cardiaques, neurologiques et psychiatriques. Thèse de médecine, Paris XIII, 1998.